

Claim Amendments

1 (currently amended): A purified peptide comprising an Rpt1 domain of an INI1/hSNF5, the Rpt1 domain having the sequence of SEQ ID NO:2, wherein the peptide inhibits HIV-1 virion production in a human cell and wherein the peptide consists of SEQ ID NO:5 or is a fragment of the INI1/hSNF5 SEQ ID NO:5.

2 (canceled)

3 (previously presented): The peptide of claim 1, further comprising an amino acid sequence not found in INI1/hSNF5.

4 (previously presented): The peptide of claim 1, further comprising a non-peptide moiety.

5 (previously presented): The peptide of claim 1, wherein the peptide does not further comprise a non-peptide moiety.

6 (original): The peptide of claim 1, wherein the human cell is a T cell.

7 (original): The peptide of claim 1, comprising SEQ ID NO:3.

8 (original): The peptide of claim 7, consisting of SEQ ID NO:3.

9 (currently amended): The peptide of claim 7 1, comprising SEQ ID NO:5 wherein the peptide is a fragment of SEQ ID NO:3.

10 (currently amended): A cell in vitro comprising the peptide of claim 1.

11 (original): The cell of claim 10, wherein the cell is a human cell.

12 (original): The cell of claim 10, wherein the cell is a hematopoietic stem cell.

13 (original): The cell of claim 10, wherein the cell is a T cell.

14 (previously presented): The cell of claim 10, wherein the cell is infected with HIV-1.

15 (original): The cell of claim 10, wherein the peptide is present in an amount sufficient to inhibit replication or virion production of HIV-1 in the cell, or spread of HIV-1 to another cell.

16 (original): The cell of claim 10, wherein the cell expresses the peptide.

17 (previously presented): A vector encoding the peptide of claim 5, wherein the peptide is expressed in a human cell when the cell is transfected with the vector.

18-23 (canceled)

24 (previously presented): The vector of claim 17 wherein, when the cell is transfected with the vector, the peptide is expressed in amounts sufficient to inhibit replication or virion production of HIV-1 in the cell, or spread of HIV-1 to another cell.

25 (currently amended): A human cell transfected with the vector of claim 17.

26-30 (canceled)

31 (previously presented): The cell of claim 25, wherein the peptide is expressed in amounts sufficient to inhibit replication or virion production of HIV-1 in the cell, or spread of HIV-1 to another cell.

32-90 (canceled)

91 (new): The peptide of claim 1, formulated in a composition that facilitates entry of the peptide into a cell.

92 (new): The cell of claim 25, wherein the cell is infected with HIV-1.